Dr Randeep Guleria, Director, AIIMS says Covaxin efficacy data is encouraging but trails will continue. This is an interim Phase 3 result based on 43 infections, but for final results, 130 infections need to be studied. But Dr Guleria says this will go a long way in promoting the vaccine program in the country.
